A Randomized, Open Phase I Trial to Evaluate the Bioavailability, Pharmacokinetics, Pharmacodynamics, Safety and Tolerance of GZR18 Tablet and Evaluate the Effect of Meal Time on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerance of GZR18 Tablet in Chinese Healthy Adult Subjects
Latest Information Update: 19 Aug 2024
At a glance
- Drugs GZR 18 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Gan&Lee Pharmaceuticals
Most Recent Events
- 12 Apr 2024 New trial record
- 08 Mar 2024 According to a Gan & Lee Pharmaceuticals media release, first subject has been dosed.